{"id":"etonogestrel-etg-implant","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Irregular bleeding or amenorrhea"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Acne"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-10","effect":"Weight gain"},{"rate":"5","effect":"Mood changes"},{"rate":"1-5","effect":"Insertion site pain or infection"}]},"_chembl":{"chemblId":"CHEMBL1531","moleculeType":"Small molecule","molecularWeight":"324.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etonogestrel is a synthetic progestin that acts on the hypothalamic-pituitary-ovarian axis to inhibit the LH surge necessary for ovulation. It also increases cervical mucus viscosity, creating a barrier to sperm penetration. The subdermal implant provides sustained hormone release over three years, maintaining contraceptive efficacy without daily administration.","oneSentence":"Etonogestrel is a progestin that prevents pregnancy by suppressing ovulation and thickening cervical mucus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:23.898Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception (prevention of pregnancy)"}]},"trialDetails":[{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT04669678","phase":"PHASE4","title":"Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-17","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":110},{"nctId":"NCT04814927","phase":"PHASE4","title":"Impact of Contraceptives on Cervico-Vaginal Mucosa","status":"COMPLETED","sponsor":"Eastern Virginia Medical School","startDate":"2021-03-01","conditions":"Mucosal Inflammation, Contraceptive; Complications, Intrauterine","enrollment":112},{"nctId":"NCT01963403","phase":"PHASE4","title":"Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2013-12","conditions":"Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Etonogestrel (ETG) implant","genericName":"Etonogestrel (ETG) implant","companyName":"University of Alabama at Birmingham","companyId":"university-of-alabama-at-birmingham","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etonogestrel is a progestin that prevents pregnancy by suppressing ovulation and thickening cervical mucus. Used for Contraception (prevention of pregnancy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}